search reports
Categories
Categories

Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2016

Report Code : gmdhc8148idb
Published Date : 31 May, 2016 | No of Pages: 79

  • Report Description
  • Table of Contents
  • Companies Mentioned
  • Related Reports
Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2016’, provides an overview of the Cervical Intraepithelial Neoplasia (CIN) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cervical Intraepithelial Neoplasia (CIN)
- The report reviews pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cervical Intraepithelial Neoplasia (CIN) therapeutics and enlists all their major and minor projects
- The report assesses Cervical Intraepithelial Neoplasia (CIN) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cervical Intraepithelial Neoplasia (CIN)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cervical Intraepithelial Neoplasia (CIN) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Cervical Intraepithelial Neoplasia (CIN) Overview 7
Therapeutics Development 8
Pipeline Products for Cervical Intraepithelial Neoplasia (CIN) - Overview 8
Pipeline Products for Cervical Intraepithelial Neoplasia (CIN) - Comparative Analysis 9
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics under Development by Companies 10
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics under Investigation by Universities/Institutes 11
Cervical Intraepithelial Neoplasia (CIN) - Pipeline Products Glance 12
Clinical Stage Products 12
Cervical Intraepithelial Neoplasia (CIN) - Products under Development by Companies 13
Cervical Intraepithelial Neoplasia (CIN) - Products under Investigation by Universities/Institutes 14
Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development 15
CEL-SCI Corporation 15
Genexine, Inc. 16
Helix BioPharma Corp. 17
Inovio Pharmaceuticals, Inc. 18
PDS Biotechnology Corporation 19
Transgene SA 20
Vaccibody AS 21
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
BLSPGAC-10 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
GLBL-101c - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
GX-188E - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
interferon alpha-2b (recombinant) - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Leukocyte Interleukin - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
PDS-0101A - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Recombinant Vector Vaccine to Target E7 for HPV Associated Cancers - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Recombinant Vector Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
TG-4001 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Vaccine for Cervical Intraepithelial Neoplasia - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
VB-1016 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
VGX-3100 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Cervical Intraepithelial Neoplasia (CIN) - Recent Pipeline Updates 49
Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects 67
Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products 68
Cervical Intraepithelial Neoplasia (CIN) - Product Development Milestones 69
Featured News & Press Releases 69
Mar 30, 2016: Inovio Pharmaceuticals HPV Immunotherapy Selected as “Best Therapeutic Vaccine” by World Vaccine Congress 69
Sep 17, 2015: Inovio Pharmaceuticals Publishes Successful Phase 2b Trial Results of Its HPV Immunotherapy in The Lancet 69
Jul 23, 2014: Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 71
Jun 11, 2014: Inovio Pharmaceuticals Clarifies Facts of its VGX-3100 Phase II Trial and Immunotherapy Technology 71
Feb 11, 2014: PDS Biotechnology Announces Treatment of First Patient with PDS0101 based on the Novel Versamune Cancer Immunotherapy Platform in a Phase 1 Clinical Trial 72
Oct 10, 2012: Inovio Pharma's DNA-based Therapeutic Cancer Vaccine Produces Immune Responses To Kill Target Cells In Phase I Study 73
May 01, 2012: Inovio Receives US Patent Protection For Synthetic Vaccine For Cervical Dysplasia And Cancer 74
Nov 11, 2011: FDA Removes Clinical Hold For Helix's Topical Interferon Alpha-2b Phase II/III Efficacy Trial IND Application 75
Oct 31, 2011: Fierce Vaccines Highlights Inovio's Cervical Dysplasia And Cancer Vaccine As One Of 10 Promising Therapeutic Vaccines 76
Oct 05, 2011: Inovio's Synthetic Vaccine For Cancer Recognized As Most Promising Research At Global Vaccine Congress 76
Appendix 78
Methodology 78
Coverage 78
Secondary Research 78
Primary Research 78
Expert Panel Validation 78
Contact Us 78
Disclaimer 79List of Tables
Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H1 2016 8
Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN) - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Products under Investigation by Universities/Institutes, H1 2016 14
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by CEL-SCI Corporation, H1 2016 15
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Genexine, Inc., H1 2016 16
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Helix BioPharma Corp., H1 2016 17
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 18
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by PDS Biotechnology Corporation, H1 2016 19
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Transgene SA, H1 2016 20
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Vaccibody AS, H1 2016 21
Assessment by Monotherapy Products, H1 2016 22
Number of Products by Stage and Target, H1 2016 24
Number of Products by Stage and Mechanism of Action, H1 2016 26
Number of Products by Stage and Route of Administration, H1 2016 28
Number of Products by Stage and Molecule Type, H1 2016 30
Cervical Intraepithelial Neoplasia (CIN) Therapeutics - Recent Pipeline Updates, H1 2016 49
Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects, H1 2016 67
Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products, H1 2016 68List of Figures
Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H1 2016 8
Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN) - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Assessment by Monotherapy Products, H1 2016 22
Number of Products by Targets, H1 2016 23
Number of Products by Stage and Targets, H1 2016 23
Number of Products by Mechanism of Actions, H1 2016 25
Number of Products by Stage and Mechanism of Actions, H1 2016 25
Number of Products by Routes of Administration, H1 2016 27
Number of Products by Stage and Routes of Administration, H1 2016 27
Number of Products by Molecule Types, H1 2016 29
Number of Products by Stage and Molecule Types, H1 2016 29
Market Intel Report Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2015
By: Global Markets Direct | Published Date : 23 December, 2015 | No of Pages : 65
Market Intel Report Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2016
By: Global Markets Direct | Published Date : 14 December, 2016 | No of Pages : 75
Market Intel Report Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2017
By: Global Markets Direct | Published Date : 30 June, 2017 | No of Pages : 67
CEL-SCI Corporation Genexine, Inc. Helix BioPharma Corp. Inovio Pharmaceuticals, Inc. PDS Biotechnology Corporation Transgene SA Vaccibody AS
Please select License
Single User Price:$ 2000
Site License Price:$ 4000
Enterprise Price:$ 6000